Search
Hot topics close

Defence Therapeutics reports promise with ARM-002 in melanoma ...

Defence Therapeutics reports promise with ARM002 in melanoma
Defence Therapeutics Inc. has announced the successful testing of a second-generation anticancer vaccine, ARM-002, using its lead anticancer molecule Accutox. When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002 led to an 80% complete

Immuno-oncology

March 27, 2024

Defence Therapeutics Inc. has announced the successful testing of a second-generation anticancer vaccine, ARM-002, using its lead anticancer molecule Accutox. When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002 led to an 80% complete response when combined with an anti-PD-1 immune-checkpoint inhibitor.

BioWorld ScienceCancerImmuno-oncologyVaccine
Similar shots
  • Enhanced Melanoma Vaccine Offers Improved Survival for Men Enhanced Melanoma Vaccine Offers Improved Survival for Men
  • Melanoma and the Wrong Site Melanoma and the Wrong Site
News Archive
This week's most popular shots